Literature DB >> 24615187

Radiation recall dermatitis after docetaxel chemotherapy. Treatment by antioxidant ointment.

Viola Duncker-Rohr1, Ulrich Freund, Felix Momm.   

Abstract

Radiation recall dermatitis (RRD) is an acute skin toxicity caused by different anticancer or antibiotic drugs within a former completely healed irradiation field. Predictive factors for RRD are not known and its mechanisms are not completely understood. A case of RRD induced by docetaxel and successfully treated by an antioxidant ointment (Mapisal(®)) is presented here. Such an ointment might be useful not only in RRD therapy, but also in the treatment of high-grade dermatitis induced by radiotherapy and thus may contribute to the improvement of patients' quality of life and to the scheduled completion of cancer therapies.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24615187     DOI： 10.1007/s00066-014-0609-1

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


  20 in total

1.  Challenges in oncology. Case 2. Radiation recall associated with docetaxel.

Authors:  Muffaddal Morkas; Donald Fleming; Michael Hahl
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

2.  Successful rechallenge after ixabepilone-induced radiation recall dermatitis using an alternative dosing strategy.

Authors:  J Neal Ford; Michael Newton; Christen Jordan; Jame Abraham
Journal:  J Oncol Pharm Pract       Date:  2012-02-09       Impact factor: 1.809

3.  Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib.

Authors:  Caroline Chung; Laura A Dawson; Anthony M Joshua; Anthony M Brade
Journal:  Anticancer Drugs       Date:  2010-02       Impact factor: 2.248

Review 4.  [Recall dermatitis caused by re-exposure to docetaxel following irradiation of the brain. Case report and review of the literature].

Authors:  B U Giesel; G G Kutz; H J Thiel
Journal:  Strahlenther Onkol       Date:  2001-09       Impact factor: 3.621

5.  Spectrophotometric skin measurements correlate with EORTC/RTOG-common toxicity criteria.

Authors:  Felix Momm; Susanne Bartelt; Kristine Haigis; Astrid Grosse-Sender; Gerlo Witucki
Journal:  Strahlenther Onkol       Date:  2005-06       Impact factor: 3.621

6.  Radiation recall pneumonitis induced by gemcitabine.

Authors:  Sebastian Schwarte; Katharina Wagner; Johann H Karstens; Michael Bremer
Journal:  Strahlenther Onkol       Date:  2007-04       Impact factor: 3.621

7.  Acute mucosal reactions in patients with head and neck cancer. Three patterns of mucositis observed during radiotherapy.

Authors:  A Wygoda; T Rutkowski; M Hutnik; K Składowski; M Goleń; B Pilecki
Journal:  Strahlenther Onkol       Date:  2013-05-23       Impact factor: 3.621

8.  Vemurafenib and radiosensitization.

Authors:  Lise Boussemart; Catherine Boivin; Joël Claveau; Yun Gan Tao; Gorana Tomasic; Emilie Routier; Christine Mateus; Eric Deutsch; Caroline Robert
Journal:  JAMA Dermatol       Date:  2013-07       Impact factor: 10.282

9.  Radiation recall reaction induced by adjuvant trastuzumab (herceptin).

Authors:  Caroline Chung; David Stuart; Mira Keyes
Journal:  Case Rep Med       Date:  2009-09-08

10.  Radiation recall dermatitis after treatment with Paclitaxel and Cisplatin.

Authors:  Seung Woo Baek; Young Joon Seo; Jun Sang Kim; Hyo Jin Lee
Journal:  Ann Dermatol       Date:  2012-04-26       Impact factor: 1.444
View more
  1 in total

Review 1.  Docetaxel-induced radiation recall dermatitis : A case report and literature review.

Authors:  Iosif Strouthos; Nikolaos Tselis; Nikolaos Zamboglou
Journal:  Strahlenther Onkol       Date:  2016-06-10       Impact factor: 3.621
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.